pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,423 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1850Endpoints1433Fierce Biotech751BioSpace741BioPharma Dive544raps245onclive165fda recalls
therapy area
allOncology12794Rare Disease3303Immunology2978Cardiology2837Hematology2278Pulmonology2221Vaccines
  • Cellectis to cut 70% of staff as it shifts focus from allogeneic CAR-T to in vivo gene editing
    Cellectis announced that roughly seven out of ten employees will be let go as the Paris‑based biotech restructures its operations. The company previously abandoned its two clinical‑stage allogenei…
    Fierce Biotech · 4d agoLayoffsNegative↗ source
  • Medicaid work requirement enforcement delayed six months to July 2027
    The Trump administration announced that states will now have an additional six months before they must begin enforcing the new Medicaid work requirements, pushing the start date to July 1, 2027. T…
    STAT · 3d agoRegulatoryNeutral↗ source
← prev
page 4 of 137
next →
118
fda medwatch113
globenewswire health73
fda press59
1837
Psychiatry & CNS1227
Ophthalmology1125
Endocrinology & Metabolism794
Pain787
Nephrology779
  • Doctors question Boston Scientific's Watchman marketing after FDA approval
    Boston Scientific's Watchman cardiac implant has been placed in more than 800,000 patients worldwide. The device eventually secured FDA approval after a protracted review, but the clearance was li…
    STAT · 4d agoRegulatoryNegative↗ source
  • Senators propose bill to limit conflicts of interest on preventive services task force
    Two senators, Angus King of Maine and Elizabeth Warren of Massachusetts, announced legislation aimed at tightening conflict‑of‑interest rules for the U.S. Preventive Services Task Force, the panel…
    STAT · 4d agoRegulatoryNeutral↗ source
  • Democrats rally behind 'Medicare for More' and 'Medikids' health coverage proposals
    Democrats are aligning around two health-care proposals aimed at expanding coverage. The "Medicare for More" plan seeks to extend Medicare to a larger share of the population, potentially all Amer…
    STAT · 3d agoNeutral↗ source
  • Synchron pauses second-generation brain-computer interface trial, says pause not safety related
    Synchron, a brain-implant startup, announced it is pausing enrollment in its second-generation brain-computer interface trial. Company officials emphasized the decision is operational and not driv…
    STAT · 4d agoNeutral↗ source
  • Investigation reveals U.S. fertility clinics offering unproven three-parent IVF to older women despite safety concerns
    The probe began after a British couple reported that they had paid a U.S.-based firm, International Fertility Group, large sums to travel abroad for an experimental fertility method that is not per…
    STAT · 4d agoNegative↗ source
  • Addiction Society Issues First Guidance on Managing Medetomidine Withdrawal
    The American Society of Addiction Medicine (ASAM) has published its first national guidance for clinicians on how to identify and treat patients experiencing withdrawal from medetomidine, a sedativ…
    STAT · 3d agoNegative↗ source
  • New organ donation rules criticized for pressuring grieving families
    A neurologist at Oregon Health & Science University recounts the case of a 22-year-old woman who was declared brain dead after a traffic accident and became a donor. He describes the intensive moni…
    STAT · 4d agoRegulatoryNegative↗ source
  • Senator-elect Abdul El-Sayed vows to rebuild trust in science amid rising measles and other health threats
    Senator-elect Abdul El‑Sayed is set to become the first epidemiologist to serve in the U.S. Senate, a timing that coincides with a series of public‑health challenges across the country. More than…
    STAT · 4d agoNeutral↗ source
  • Cerevance appoints Karl Kieburtz as new chief medical officer
    STAT+ runs a regular column that tracks personnel moves in the pharmaceutical sector. The piece highlights recent hires, promotions and transfers across companies. Cerevance announced that Karl Ki…
    STAT · 4d agoNeutral↗ source
  • New Alzheimer’s biomarker tests raise existential concerns for people without symptoms
    Jason Karlawish, a professor of medicine and neurology at the University of Pennsylvania, reflects on the personal impact of learning one may develop Alzheimer’s before any symptoms appear. He fram…
    STAT · 4d agoNeutral↗ source
  • Marrow extracts $120M series B to advance preclinical blood disease therapy
    A new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in combined funding and a preclinical lead program aimed at sickle cell disease and beta th…
    Fierce Biotech · 4d agoNeutral↗ source
  • Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trial
    Regeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.
    Fierce Biotech · 4d agoNeutral↗ source
  • Local schools launch experiments to curb teen phone addiction
    A teacher in Milwaukee asked her digital journalism class to write about their relationship with devices, uncovering disturbing accounts of constant phone use and online abuse. The students descri…
    STAT · 4d agoNegative↗ source
  • American Cancer Society updates prostate cancer screening guidance
    For the first time in 16 years, the American Cancer Society (ACS) has updated its guideline for prostate cancer screening as it drives to boost detection of the disease before it spreads.
    Fierce Biotech · 4d ago↗ source
  • Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with Sanofi for DNA therapies
    Seawolf Therapeutics announced it has closed a $100 million financing round. The capital came from a seed round led by Versant Ventures and a Series A round that included investors such as Eli Lill…
    Fierce Biotech · 5d agoDealPositive↗ source
  • Sofinnova Partners closes €725 million (≈$815 million) Crossover II fund to back ~15 European clinical-stage biotech firms
    Sofinnova Partners announced the closing of its largest fund to date, Crossover II, with €725 million (about $815 million) in capital. The fund plans to invest in roughly 15 clinical‑stage compani…
    Fierce Biotech · 4d agoDealPositive↗ source
  • Scientists release detailed basal ganglia cell map, uncover new neuron linked to schizophrenia
    Scientists from a large international collaboration have created the most detailed map of the basal ganglia, a brain region that coordinates movement and emotion. The effort profiled over 25 millio…
    STAT · 5d agoPositive↗ source
  • Bristol Myers Squibb reshuffles R&D leadership as chief research officer departs and CMO takes over combined unit
    Bristol Myers Squibb announced a restructuring of its research and development organization, merging the separate research and development divisions into a single unit. The new combined R&D unit w…
    Fierce Biotech · 5d agoNeutral↗ source
  • FDA faces over 1,000 vacant positions as staffing shortage strains pharma oversight
    The FDA currently has more than a thousand open jobs, reflecting a deep staffing shortfall that began after a large wave of departures last year. The agency lost 1,343 employees at its CBER and CD…
    BioPharma Dive · 5d agoNegative↗ source
  • Senate debate looms over Heidi Overton’s potential FDA nomination
    The article raises the question of whether Heidi Overton will be nominated to head the FDA and how the Senate might respond. It notes that a committee chair typically schedules a confirmation vote…
    STAT · 5d agoRegulatoryNeutral↗ source
  • New documents spark fresh concerns over Medicare's AI prior-authorization pilot
    New documents have been released that raise additional questions about Medicare's experiment using artificial intelligence to handle prior-authorization requests. The pilot, which seeks to automat…
    STAT · 5d agoRegulatoryNegative↗ source
  • FDA shelves fast-track drug review program launched in 2025
    The U.S. Food and Drug Administration announced it is suspending the fast-track drug review initiative that was introduced in June 2025 under former commissioner Marty Makary. The program, called…
    STAT · 5d agoRegulatoryNegative↗ source
  • American Cancer Society recommends routine PSA screening for men 50-69, strengthens guidance for high-risk groups
    The American Cancer Society (ACS) has updated its prostate-cancer screening guidelines, now advising men at average risk aged 50 to 69 to have a PSA blood test every two years. This replaces the 20…
    STAT · 5d agoRegulatoryPositive↗ source